Mediwound Stock Analysis
MDWD Stock | USD 20.44 0.37 1.84% |
Mediwound is undervalued with Real Value of 26.06 and Target Price of 30.0. The main objective of Mediwound stock analysis is to determine its intrinsic value, which is an estimate of what Mediwound is worth, separate from its market price. There are two main types of Mediwound's stock analysis: fundamental analysis and technical analysis.
The Mediwound stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Mediwound's ongoing operational relationships across important fundamental and technical indicators.
Mediwound | Build AI portfolio with Mediwound Stock |
Mediwound Stock Analysis Notes
About 18.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 2.05. Mediwound had not issued any dividends in recent years. The entity had 1:7 split on the 20th of December 2022. MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel. Mediwound operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Mediwound contact the company at 972 7 797 14100 or learn more at https://www.mediwound.com.Mediwound Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Mediwound's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Mediwound or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company reported the previous year's revenue of 20.22 M. Net Loss for the year was (30.22 M) with profit before overhead, payroll, taxes, and interest of 2.77 M. | |
Mediwound currently holds about 10.41 M in cash with (13.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31. | |
Mediwound has a poor financial position based on the latest SEC disclosures | |
Roughly 18.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from news.google.com: Is MediWound Ltd. a good long term investment - Unmatched profit potential - Autocar Professional |
Mediwound Upcoming and Recent Events
21st of March 2024 Upcoming Quarterly Report | View | |
4th of June 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
21st of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Mediwound Largest EPS Surprises
Earnings surprises can significantly impact Mediwound's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-03-21 | 2023-12-31 | -0.23 | -0.19 | 0.04 | 17 | ||
2022-05-17 | 2022-03-31 | -0.76 | -0.84 | -0.08 | 10 | ||
2021-05-05 | 2021-03-31 | -0.78 | -0.7 | 0.08 | 10 |
Mediwound Environmental, Social, and Governance (ESG) Scores
Mediwound's ESG score is a quantitative measure that evaluates Mediwound's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Mediwound's operations that may have significant financial implications and affect Mediwound's stock price as well as guide investors towards more socially responsible investments.
Mediwound Thematic Classifications
In addition to having Mediwound stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
![]() | Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Mediwound Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | State Street Corp | 2025-03-31 | 72.1 K | Sargent Investment Group, Llc | 2025-03-31 | 68.7 K | Ubs Group Ag | 2025-03-31 | 67.8 K | Dafna Capital Management Llc | 2025-03-31 | 64.5 K | Vanguard Group Inc | 2025-03-31 | 61.5 K | Legato Capital Management Llc | 2025-03-31 | 43.2 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 36.6 K | Meitav Dash Investments Ltd | 2025-03-31 | 31.5 K | Charles Schwab Investment Management Inc | 2025-03-31 | 22.5 K | Investors Finance Co Plc | 2025-03-31 | 872.1 K | Yelin Lapidot Holdings Management Ltd | 2025-03-31 | 858 K |
Mediwound Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 221.13 M.Mediwound Profitablity
The company has Profit Margin (PM) of (1.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.32) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.32.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.41) | (0.43) | |
Return On Capital Employed | (0.41) | (0.43) | |
Return On Assets | (0.41) | (0.43) | |
Return On Equity | (0.97) | (1.02) |
Management Efficiency
Mediwound has return on total asset (ROA) of (0.1988) % which means that it has lost $0.1988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7792) %, meaning that it created substantial loss on money invested by shareholders. Mediwound's management efficiency ratios could be used to measure how well Mediwound manages its routine affairs as well as how well it operates its assets and liabilities. As of July 22, 2025, Return On Tangible Assets is expected to decline to -0.43. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, Mediwound's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.29, whereas Non Currrent Assets Other are forecasted to decline to about 310.2 K.Last Reported | Projected for Next Year | ||
Book Value Per Share | 3.13 | 3.59 | |
Tangible Book Value Per Share | 3.12 | 3.28 | |
Enterprise Value Over EBITDA | (6.21) | (6.52) | |
Price Book Value Ratio | 5.69 | 6.09 | |
Enterprise Value Multiple | (6.21) | (6.52) | |
Price Fair Value | 5.69 | 6.09 | |
Enterprise Value | 174.6 M | 149 M |
Effective management at Mediwound has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Technical Drivers
As of the 22nd of July, Mediwound secures the Risk Adjusted Performance of 0.1375, downside deviation of 2.1, and Mean Deviation of 1.73. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mediwound, as well as the relationship between them. Please verify Mediwound treynor ratio, and the relationship between the standard deviation and downside variance to decide if Mediwound is priced some-what accurately, providing market reflects its recent price of 20.44 per share. Given that Mediwound has jensen alpha of 0.2526, we recommend you to check Mediwound's last-minute market performance to make sure the company can sustain itself at a future point.Mediwound Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Mediwound for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Mediwound short-term fluctuations and highlight longer-term trends or cycles.
Mediwound Outstanding Bonds
Mediwound issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mediwound uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mediwound bonds can be classified according to their maturity, which is the date when Mediwound has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View |
Mediwound Predictive Daily Indicators
Mediwound intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mediwound stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Mediwound Corporate Filings
6K | 21st of May 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 15th of May 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
12th of May 2025 Other Reports | ViewVerify | |
6K | 7th of April 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
28th of March 2025 Other Reports | ViewVerify | |
6K | 19th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 12th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
11th of February 2025 Other Reports | ViewVerify |
Mediwound Forecast Models
Mediwound's time-series forecasting models are one of many Mediwound's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mediwound's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Mediwound Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Mediwound prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mediwound shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mediwound. By using and applying Mediwound Stock analysis, traders can create a robust methodology for identifying Mediwound entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (1.49) | (1.57) | |
Operating Profit Margin | (0.96) | (1.01) | |
Net Loss | (1.49) | (1.57) | |
Gross Profit Margin | 0.13 | 0.14 |
Current Mediwound Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mediwound analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mediwound analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
30.0 | Strong Buy | 6 | Odds |
Most Mediwound analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Mediwound stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Mediwound, talking to its executives and customers, or listening to Mediwound conference calls.
Mediwound Stock Analysis Indicators
Mediwound stock analysis indicators help investors evaluate how Mediwound stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mediwound shares will generate the highest return on investment. By understating and applying Mediwound stock analysis, traders can identify Mediwound position entry and exit signals to maximize returns.
Begin Period Cash Flow | 11.9 M | |
Common Stock Shares Outstanding | 10 M | |
Total Stockholder Equity | 31.2 M | |
Total Cashflows From Investing Activities | -8.4 M | |
Tax Provision | 61 K | |
Property Plant And Equipment Net | 20.8 M | |
Cash And Short Term Investments | 9.2 M | |
Cash | 9.2 M | |
Accounts Payable | 4.1 M | |
Net Debt | -2.6 M | |
50 Day M A | 20.1181 | |
Total Current Liabilities | 26.5 M | |
Other Operating Expenses | 39.6 M | |
Non Current Assets Total | 21.3 M | |
Non Currrent Assets Other | 439 K | |
Stock Based Compensation | 3.1 M |
Complementary Tools for Mediwound Stock analysis
When running Mediwound's price analysis, check to measure Mediwound's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediwound is operating at the current time. Most of Mediwound's value examination focuses on studying past and present price action to predict the probability of Mediwound's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediwound's price. Additionally, you may evaluate how the addition of Mediwound to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |